Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study
Authors
Keywords
Sodium–glucose co-transporter 2 inhibitors, Cardiovascular disease, Heart failure, Real-world data
Journal
Cardiovascular Diabetology
Volume 18, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-09-24
DOI
10.1186/s12933-019-0919-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial
- (2019) David Fitchett et al. CIRCULATION
- Heart failure and type 2 diabetes: From CVOTs, with hope
- (2019) Dario Giugliano et al. DIABETES OBESITY & METABOLISM
- Cardiovascular outcome trials of glucose-lowering medications: an update
- (2019) Philip Home DIABETOLOGIA
- The Chang Gung Research Database-A multi-institutional electronic medical records database for real-world epidemiological studies in Taiwan
- (2019) Shih-Chieh Shao et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
- (2019) Jennifer R Donnan et al. BMJ Open
- ASSOCIATION OF GLYCEMIC VARIABILITY WITH LEFT VENTRICULAR DIASTOLIC FUNCTION IN TYPE 2 DIABETES MELLITUS
- (2019) Shun Yokota et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Dapagliflozin and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Prior Myocardial Infarction: A Sub-analysis From DECLARE TIMI-58 Trial
- (2019) Remo H. M. Furtado et al. CIRCULATION
- Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials
- (2019) Giovanni Musso et al. BMJ-British Medical Journal
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Exploration of the clinical benefits of sodium glucose co-transporter 2 inhibitors in diabetic patients with concomitant heart failure
- (2018) Atsushi Tanaka et al. Cardiovascular Diabetology
- Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors
- (2018) Sarayut Lahnwong et al. Cardiovascular Diabetology
- SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial
- (2018) M. V. Karg et al. Cardiovascular Diabetology
- Sodium-glucose co-transporter-2 inhibitors, the latest residents on the block: Impact on glycaemic control at a general practice level in England
- (2018) Adrian H. Heald et al. DIABETES OBESITY & METABOLISM
- SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: A systematic review and meta-analysis
- (2018) Man Guo et al. DIABETES OBESITY & METABOLISM
- Empagliflozin in women with type 2 diabetes and cardiovascular disease – an analysis of EMPA-REG OUTCOME®
- (2018) Bernard Zinman et al. DIABETOLOGIA
- SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
- (2018) Subodh Verma et al. DIABETOLOGIA
- A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment
- (2018) Agostino Consoli et al. Expert Opinion On Drug Safety
- Association of Varicose Veins With Incident Venous Thromboembolism and Peripheral Artery Disease
- (2018) Shyue-Luen Chang et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes
- (2018) Sean L. Zheng et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs
- (2018) Mikhail Kosiborod et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
- (2018) Tricia Santos Cavaiola et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure
- (2018) Fumitaka Soga et al. Cardiovascular Diabetology
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
- (2018) DIABETES CARE
- Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL
- (2018) Lindsay E. Clegg et al. DIABETES CARE
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study
- (2018) Peter Ueda et al. BMJ-British Medical Journal
- Visit-to-visit blood pressure variability is a risk factor for all-cause mortality and cardiovascular disease
- (2017) Jianqi Wang et al. JOURNAL OF HYPERTENSION
- Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
- (2017) Kåre I Birkeland et al. Lancet Diabetes & Endocrinology
- Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events
- (2017) Kenneth W. Mahaffey et al. CIRCULATION
- Association of In-Hospital Mortality and Dysglycemia in Septic Patients
- (2017) Hsiao-Yun Chao et al. PLoS One
- Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?
- (2016) Subodh Verma et al. DIABETES CARE
- Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis
- (2016) F. Zaccardi et al. DIABETES OBESITY & METABOLISM
- Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects
- (2016) Atsuo Tahara et al. JOURNAL OF PHARMACOLOGICAL SCIENCES
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study
- (2016) Michael A Weber et al. Lancet Diabetes & Endocrinology
- Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality
- (2015) Paul Muntner et al. ANNALS OF INTERNAL MEDICINE
- Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study
- (2015) S. Sha et al. DIABETES OBESITY & METABOLISM
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension
- (2014) Ilkka Tikkanen et al. DIABETES CARE
- Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
- (2014) André J. Scheen DRUGS
- Validation of Acute Myocardial Infarction Cases in the National Health Insurance Research Database in Taiwan
- (2014) Ching-Lan Cheng et al. JOURNAL OF EPIDEMIOLOGY
- Prespecified Falsification End Points
- (2013) Vinay Prasad et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Kidney function and the risk of cardiovascular disease in patients with type 2 diabetes
- (2013) Yujie Wang et al. KIDNEY INTERNATIONAL
- Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial
- (2013) Michael Roden et al. Lancet Diabetes & Endocrinology
- Negative Controls
- (2010) Marc Lipsitch et al. EPIDEMIOLOGY
- Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
- (2010) The Emerging Risk Factors Collaboration LANCET
- Validation of the national health insurance research database with ischemic stroke cases in Taiwan
- (2010) Ching-Lan Cheng et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
- (2008) J. F. List et al. DIABETES CARE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started